Research programme: p53 targeted cancer therapeutics - Eleos

Drug Profile

Research programme: p53 targeted cancer therapeutics - Eleos

Alternative Names: Antisense p53 therapeutics - Eleos

Latest Information Update: 18 Jul 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eleos
  • Class Antisense elements
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 18 Jul 2012 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 12 Jul 2012 AVI Biopharma is now called Sarepta Therapeutics
  • 31 Dec 2008 The collaboration with Eleos and AVI BioPharma is still active
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top